CSBio CSBio

X
[{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to Camurus\u2019 CAM2029 to Treat Polycystic Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Camurus"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            CAM2029 is a ready-to-use, long-acting subcutaneous depot of octreotide used for the treatment of autosomal dominant polycystic liver disease. CAM2029 is developed for enhanced octreotide exposure and easy self-administration by patients using a prefilled pen injector.

            Lead Product(s): Octreotide Acetate

            Therapeutic Area: Genetic Disease Product Name: CAM2029

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY